Phase transformation considerations during process development and manufacture of solid oral dosage forms

Advanced Drug Delivery Reviews

Volumn 56, Issue 3, 2004, Pages 371-390

  Zhang, Geoff G Z ^a   Law, Devalina ^a   Schmitt, Eric A ^a   Qiu, Yihong ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Amorphous; Hydrate; Mechanism; Pharmaceutical processing; Phase transformation; Polymorph; Solid oral dosage forms

Indexed keywords

PHASE TRANSITIONS; PROCESS ENGINEERING; REACTION KINETICS;

POLYMORPHISM; SOLID ORAL DOSAGE;

DRUG DOSAGE;

ACETYLSALICYLIC ACID; ANTICONVULSIVE AGENT; CARBAMAZEPINE; DIGOXIN; DISINTEGRATING AGENT; ESTRADIOL; EXCIPIENT; GLIDING AGENT; LUBRICATING AGENT; MANNITOL; OLANZAPINE; PROTEINASE INHIBITOR; RITONAVIR; SPIRONOLACTONE; THEOPHYLLINE; THIAMINE;

COMPRESSION; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG COATING; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG HYDROLYSIS; DRUG SOLUBILITY; ENCAPSULATION; HYDRATION; INFRARED SPECTROMETRY; MICROSCOPY; NEAR INFRARED SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PHASE TRANSITION; PRIORITY JOURNAL; RAMAN SPECTROMETRY; REVIEW; SOLID STATE; TABLET; TEMPERATURE DEPENDENCE; THERMODYNAMICS; THERMOGRAVIMETRY; X RAY DIFFRACTION; X RAY POWDER DIFFRACTION;

EID: 1042298067     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2003.10.009     Document Type: Article

References (90)

1. Grant D.J.W. Theory and origin of polymorphism. Brittain H.G. Polymorphism in Pharmaceutical Solids. vol. 95:1999;1-33 Marcel Dekker, New York.
2. Morris K.R., Griesser U.J., Eckhardt C.J., Stowell J.G. Theoretical approach to physical transformations of active pharmaceutical ingredients during manufacturing processes. Adv. Drug Deliv. Rev. 48:2001;91-114.
3. Haleblian J.K., McCrone W.C. Pharmaceutical applications of polymorphism. J. Pharm. Sci. 58:1969;911-929.
4. Threlfall T.L. Analysis of organic polymorphs a review. Analyst. 120:1995;2435-2460.
5. Oberholtzer E.R., Brenner G.S. Cefoxitin sodium: solution and solid-state chemical stability studies. J. Pharm. Sci. 68:1979;863-866.
6. Carstensen J.T., Morris T. Chemical stability of indomethacin in the solid amorphous and molten states. J. Pharm. Sci. 82:1993;657-659.
7. Shalaev E.Y., Shalaeva M., Byrn S.R., Zografi G. Effects of processing on the solid-state methyl transfer of tetraglycine methyl ester. Int. J. Pharm. 152:1997;75-88.
8. Sukenik C.N., Bonapace J.A.P., Mandel N.S., Bergman R.G., Lau P.Y., Wood G. Enhancement of a chemical reaction rate by proper orientation of reacting molecules in the solid state. J. Am. Chem. Soc. 97:1975;5290-5291.
9. Sukenik C.N., Bonapace J.A.P., Mandel N.S., Lau P.Y., Wood G., Bergman R.G. A kinetic and X-ray diffraction study of the solid-state rearrangement of methyl p-dimethylaminobenzenesulfonate. Reaction rate enhancement due to proper orientation in a crystal. J. Am. Chem. Soc. 99:1977;851-858.
10. Pikal M.J., Rigsbee D.R. The stability of insulin in crystalline and amorphous solids: observation of greater stability for the amorphous form. Pharm. Res. 14:1997;1379-1387.
11. Garner W.E. Chemistry of the Solid State. 1955;Academic Press, New York.
12. Van Campen L., Monkhouse D.C. Solid-state reactions - theoretical and experimental aspects. Drug Dev. Ind. Pharm. 10:1984;1175-1276.
13. Byrn S.R., Pfeiffer R.R., Stowell J.G. Solid-State Chemistry of Drugs. 2nd ed. 1999;SSCI Inc, West Lafayette, IN.
14. Zhou D., Schmitt E.A., Zhang G.G.Z., Law D., Wight C.A., Vyazovkin S., Grant D.J.W. Model-free treatment of the dehydration kinetics of nedocromil sodium trihydrate. J. Pharm. Sci. 92:2003;1367-1376.
15. Zhou D., Schmitt E.A., Zhang G.G.Z., Law D., Wight C.A., Vyazovkin S., Grant D.J.W. Crystallization kinetics of amorphous nifedipine studied by model-fitting and model-free approaches. J. Pharm. Sci. 92:2003;1779-1792.
16. Mullin J.W. Crystallization. 3rd ed. 1992;Butterworth-Heinemann, Oxford.
17. Cardew P.T., Davey R.J. The kinetics of solvent-mediated phase-transformations. Proc. R. Soc. London A Math. Phys. Eng. Sci. 398:1985;415-428.
18. Rodríguez-Hornedo N., Lechuga-Ballesteros D., Wu H.J. Phase transition and heterogeneous/epitaxial nucleation of hydrated and anhydrous theophylline crystals. Int. J. Pharm. 85:1992;149-162.
19. Zhang G.G.Z., Gu C., Zell M.T., Burkhardt R.T., Munson E.J., Grant D.J.W. Crystallization and transitions of sulfamerazine polymorphs. J. Pharm. Sci. 91:2002;1089-1100.
20. Dunitz J.D. Phase changes and chemical reactions in molecular crystals. Acta Crystallogr., B. 51:1995;619-631.
21. Giron D. Thermal analysis and calorimetric methods in the characterization of polymorphs and solvates. Thermochim. Acta. 248:1995;1-59.
22. Jasti B.R., Du J., Vasavada R.C. Characterization of thermal behavior of etoposide. Int. J. Pharm. 118:1995;161-167.
23. Han J., Suryanarayanan R. Influence of environmental conditions on the kinetics and mechanism of dehydration of carbamazepine dihydrate. Pharm. Dev. Technol. 21:1998;587-596.
24. Willart J.F., De Gusseme A., Hemon S., Descamps M., Leveiller F., Rameau A. Vitrification and polymorphism of trehalose induced by dehydration of trehalose dihydrate. J. Phys. Chem. B. 106:2002;3365-3370.
25. Mullins J., Macek T. Some pharmaceutical properties of novobiocin. J. Am. Pharm. Assoc. Sci. Ed. 49:1960;245-248.
26. Hancock B.C., Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res. 17:2000;397-404.
27. Andronis V., Zografi G. The molecular mobility of supercooled amorphous indomethacin as a function of temperature and relative humidity. Pharm. Res. 15:1998;835-842.
28. Kauzmann W. The nature of the glassy state and the behavior of liquids at low temperatures. Chem. Rev. 43:1948;219-256.
29. Angell C.A. Formation of glasses from liquids and biopolymers. Science. 267:1995;1924-1935.
30. Hancock B.C., Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 86:1997;1-12.
31. Hatley R.H.M. Glass fragility and the stability of pharmaceutical preparations - excipient selection. Pharm. Dev. Technol. 2:1997;257-264.
32. Zhou D., Zhang G.G.Z., Law D., Grant D.J.W., Schmitt E.A. Physical stability of amorphous pharmaceuticals: importance of configurational thermodynamic quantities and molecular mobility. J. Pharm. Sci. 91:2002;1863-1972.
33. Gutsov I., Kashtiev D., Avramov I. Nucleation and crystallization in glass-forming melts: old problems and new questions. J. Non-Cryst. Solids. 73:1985;477-499.
34. Ahlneck C., Zografi G. The molecular basis of moisture effect on the physical and chemical stability of drugs in the solid-state. Int. J. Pharm. 62:1990;87-95.
35. Andronis V., Yoshioka M., Zografi G. Effect of sorbed water on the crystallization of indomethacin from the amorphous state. J. Pharm. Sci. 86:1997;346-351.
36. Zallen R. The Physics of Amorphous solids. 1983;3 Wiley, New York.
37. Saleki-Gerhardt A., Stowell J.G., Byrn S.R., Zografi G. Hydration and dehydration of crystalline and amorphous forms of raffinose. J. Pharm. Sci. 84:1995;318-323.
38. Ding S.P., Fan J., Green J.L., Lu Q., Sanchez E., Angell C.A. Vitrification of trehalose by water loss from its crystalline dihydrate. J. Thermal Anal. 47:1996;1391-1405.
39. Li Y., Han J., Zhang G.G.Z., Grant D.J.W., Suryanarayanan R. In situ dehydration of carbamazepine dihydrate: a novel technique to prepare amorphous anhydrous carbamazepine. Pharm. Dev. Technol. 5:2000;257-266.
40. Räsänen E., Rantanen J., Jørgensen A., Karjalainen M., Paakkari T., Yliruusi J. Novel identification of pseudopolymorphic changes of theophylline during wet granulation using near infrared spectroscopy. J. Pharm. Sci. 90:2001;389-396.
41. Rudnic E., Schwartz J.B. Solid Oral Dosage Forms. Remington's Pharmaceutical Sciences. 18th ed. 1990;1633-1647 Mark Publishing, Easton, PA.
42. Lieberman H.A., Lachman L., Schwartz J.B. 2nd ed. (revised and expanded) Pharmaceutical Dosage Forms: Tablets. vol. 1:1989;Marcel Dekker, New York.
43. Lieberman H.A., Lachman L., Schwartz J.B. 2nd ed. (revised and expanded) Pharmaceutical Dosage Forms: Tablets. vol. 2:1990;Marcel Dekker, New York.
44. York P. Strategies for particle design using supercritical fluid technologies. Pharm. Sci. Technol. Today. 2:1999;430-440.
45. Ostwald W. The formation and changes of solids. Z. Physik Chem. 22:1897;289-330.
46. Verma A.R., Krishna P. Polymorphism and Polytypism in Crystals. 1966;15-30 Wiley, New York.
47. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J. Pharm. Pharmacol. 50:1998;375-382.
48. Kearney P. The Zydis oral fast-dissolving dosage form. Drugs Pharm. Sci. 126:2003;191-201.
49. Chan H.K., Doelker E. Polymorphic transformation of some drugs under compression. Drug Dev. Ind. Pharm. 11:1985;315-332.
50. Sekiguchi K., Obi N. Absorption of eutectic mixtures: I. A comparison of the behavior of a eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem. Pharm. Bull. 9:1961;866-872.
51. Law D., Wang W., Schmitt E.A., Qiu Y., Krill S.L., Fort J.J. Properties of rapidly dissolving eutectic mixtures of poly(ethylene glycol) and fenofibrate: the eutectic microstructure. J. Pharm. Sci. 92:2003;505-515.
52. K.R. Engh, Y. Qiu, T.L. Reiland, Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption, US Patent No. 6180138, 2001.
53. Simonelli A.P., Mehta S.C., Higuchi W.I. Dissolution rate of high energy polyvinylpyrrolidone (PVP)-sulfathiazole coprecipitates. J. Pharm. Sci. 58:1969;538-549.
54. Yoshika M., Hancock B., Zografi G. Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates. J. Pharm. Sci. 84:1995;983-986.
55. Law D., Krill S.L., Schmitt E.A., Fort J.J., Qiu Y., Wang W., Porter W.R. Physicochemical considerations in the preparation of amorphous ritonavir-poly(ethylene glycol) 8000 solid dispersions. J. Pharm. Sci. 90:2001;1015-1025.
56. Law D., Schmitt E.A., Marsh K., Everitt E.A., Wang W., Fort J.J., Krill S.L., Qiu Y. Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluation. In review. J. Pharm. Sci. 2003.
57. Ward G.H., Schultz R.K. Process-induced crystallinity changes in albuterol sulfate and its effect on powder physical stability. Pharm. Res. 12:1995;773-779.
58. Ndindayino F., Henrist D., Kiekens F., Van den Mooter G., Vervaet C., Remon J.P. Direct compression properties of melt-extruded isomalt. Int. J. Pharm. 235:2002;149-157.
59. Qiu Y., Fort J.J., Trivedi J., Gerhardt A.H., Mayer P., Briskin J., Schilling R.J. Effect of physicochemical and formulation variables on the in vivo absorption of ABT-761. Drug Dev. Ind. Pharm. 28:2002;287-295.
60. Wardrop J., Engh K., Faitsch L., Law D., Ling C., Qiu Y. Investigation of a process induced instability due to formation of amorphous ABT-232 in tablets. AAPS 16th Annual Meeting, Denver, CO:2001.
61. Leeson L., Mattocks A.M. Decomposition of aspirin in the solid-state. J. Am. Pharm. Assoc. 47:1958;329-333.
62. Carstensen J.T., Attarchi F., Hou X.P. Decomposition of aspirin in the solid-state in the presence of limited amounts of moisture. J. Pharm. Sci. 74:1985;741-745.
63. Carstensen J.T., Attarchi F. Decomposition of aspirin in the solid-state in the presence of limited amounts of moisture. III: effect of temperature and a possible mechanism. J. Pharm. Sci. 77:1988;318-321.
64. Hancock B.C., Zografi G. Effects of solid-state processing on the water vapor sorption by aspirin. J. Pharm. Sci. 85:1996;246-248.
65. Watanabe A., Tasaki S., Wada Y., Nakamachi H. Polymorphism of thiamine hydrochloride II. Crystal structure of thiamine hydrochloride hemihydrate and its stability. Chem. Pharm. Bull. 27:1979;2751-2759.
66. Wöstheinrich K., Schmidt P.C. Polymorphic changes of thiamine hydrochloride during granulation and tableting. Drug Dev. Ind. Pharm. 27:2001;481-489.
67. Rustichelli C., Gamberini G., Ferioli V., Gamberini M.C., Ficarra R., Tommasini S. Solid-state study of polymorphic drugs: carbamazepine. J. Pharm. Biomed. Anal. 23:2000;41-54.
68. Meyer M.C., Straughn A.B., Jarvi E.J., Wood G.C., Pelsor F.R., Shah V.P. The bioinequivalence of carbamazepine tablets with a history of clinical failures. Pharm. Res. 9:1992;1612-1616.
69. Otsuka M., Hasegawa H., Matsuda Y. Effect of polymorphic transformation during the extrusion-granulation process on the pharmaceutical properties of carbamazepine granules. Chem. Pharm. Bull. 45:1997;894-898.
70. Otsuka M., Hasegawa H., Matsuda Y. Effect of polymorphic forms of bulk powders on pharmaceutical properties of carbamazepine granules. Chem. Pharm. Bull. 47:1999;852-856.
71. Murphy D., Rodríguez-Cintron F., Langevin B., Kelly R.C., Rodríguez-Hornedo N. Solution-mediated phase transformation of anhydrous to dihydrate carbamazepine and the effect of lattice disorder. Int. J. Pharm. 246:2002;121-134.
72. Phadnis N.V., Suryanarayanan R. Polymorphism in anhydrous theophylline - implications for the dissolution rate of theophylline tablets. J. Pharm. Sci. 86:1997;1256-1263.
73. Herman J., Remon J.P., Visavarungroj N., Schwartz J.B., Klinger G.H. Formation of theophylline monohydrate during the pelletisation of microcrystalline cellulose-anhydrous theophylline blends. Int. J. Pharm. 42:1988;15-18.
74. Otsuka M., Ohfusa T., Matsuda Y. Effect of binders on polymorphic transformation kinetics of carbamazepine in aqueous solution. Colloids Surf. B: Biointerf. 17:2000;145-152.
75. Garti N., Sato K. Effects of surfactants on transition kinetics of stearic acid polymorphs. J. Am. Oil Chem. Soc. 63:1986;236-239.
76. Garti N., Zour H. The effect of surfactants on the crystallization and polymorphic transformation of glutamic acid. J. Cryst. Growth. 172:1997;486-498.
77. Garcia E., Hoff C., Veesler S. Dissolution and phase transition of pharmaceutical compounds. J. Cryst. Growth. 237-239:2002;2233-2239.
78. Airaksinen S., Luukkonen P., Jørgensen A., Karjalainen M., Rantanena J., Yliruusi J. Effects of excipients on hydrate formation in wet masses containing theophylline. J. Pharm. Sci. 92:2003;516-528.
79. Zhu H., Yuen C., Grant D.J.W. Influence of water activity in organic solvent+water mixtures on the nature of the crystallizing drug phase. 1. Theophylline. Int. J. Pharm. 135:1996;151-160.
80. Roberts R.J., Rowe R.C. The Young's modulus of pharmaceutical materials. Int. J. Pharm. 37:1987;15-18.
81. Duncan-Hewitt W.C., Weatherly G.C. Modeling the uniaxial compaction of pharmaceutical powders using the mechanical properties of single crystals: II. Brittle materials. J. Pharm. Sci. 79:1990;273-278.
82. Danielson D.W., Morehead W.T., Rippie E.C. Unloading and postcompression viscoelastic stress versus strain behavior of pharmaceutical solids. J. Pharm. Sci. 72:1983;342-345.
83. Fachaux J.-M., Guyot-Hermann A.-M., Guyot J.-C., Conflant P., Drache M., Huvenne J.P., Bouche R. Compression ability improvement by solvation/ desolvation process: application to paracetamol for direct compression. Int. J. Pharm. 99:1993;99-107.
84. Fachaux J.-M., Guyot-Hermann A.-M., Guyot J.-C., Conflant P., Drache M., Veesler S., Boistelle R. Pure paracetamol for direct compression Part I. Development of sintered-like crystals of paracetamol. Powder Tech. 82:1995;123-128.
85. Fachaux J.-M., Guyot-Hermann A.-M., Guyot J.-C., Conflant P., Drache M., Veesler S., Boistelle R. Pure Paracetamol for direct compression Part II. Study of the physicochemical and mechanical properties of sintered-like crystals of paracetamol. Powder Tech. 82:1995;129-133.
86. Hess H. Tablets under the microscope. Pharm. Technol. 2:1978;38-57.
87. Di Martino P., Guyot-Hermann A.-M., Conflant P., Drache M., Guyot J.-C. A new pure paracetamol for direct compression: the orthorhombic form. Int. J. Pharm. 128:1996;1-8.
88. Nichols G., Frampton C.S. Physicochemical characterization of the orthorhombic polymorph of paracetamol crystallized from solution. J. Pharm. Sci. 87:1998;684-693.
89. Joiris E., Di Martino P., Berneron C., Guyot-Hermann A.-M., Guyot J.-C. Compression behavior of orthorhombic paracetamol. Pharm. Res. 15:1998;1122-1130.
90. Hancock B.C., Carlson G.T., Ladipo D.D., Langdon B.A., Mullarney M.P. Comparison of the mechanical properties of the crystalline and amorphous forms of a drug substance. Int. J. Pharm. 241:2002;73-84.